Bayer is a life sciences group based in Germany. Co.'s operations are organized along three divisions: Pharmaceuticals (engaged in prescription pharmaceuticals for cardiology and women's healthcare); Consumer Health (engaged in non-prescription products in dermatology, dietary supplement, analgesic, gastrointestinal, allergy, cold and flu, foot care, sun protection and cardiovascular risk prevention categories); and CropScience (engaged in the development of seeds and plant traits; crop protection; and for gardens, the green industry and non-agricultural pest control). Co. also maintains an Animal Health business unit engaged in the development of products for farm and companion animals.
  • TickerBAY001
  • ISINDE000BAY0017
  • SectorPharmaceuticals & Biotechnology
  • CountryGermany

Analysts

Jean-Jacques Le Fur

BAYER: Darolutamide not better than Xtandi in prostate cancer | NEUTRAL | EUR81

BAYER - NEUTRAL | EUR81(+24%) Darolutamide not better than Xtandi in prostate cancer Significant improvement of free survival Darolutamide will have to compete with Xtandi We are less optimistic than Bayer regarding peak sales Neutral rating reiterated

Bayer – Proxinvest Corporate Governance Rating ® : C

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Damien Conover

Morningstar | BAYN Updated Forecasts and Estimates from 17 Jan 2019

During Bayer's capital markets day, the firm provided more details around one-time costs related to restructuring the business that led to a 3% reduction in our fair value estimate (with a slightly larger reduction to the ADR due to changes in currency rates). While we believe the restructuring makes strategic sense, the related one-time costs needed to implement the restructuring of over EUR 4 billion are higher than we expected. Despite the reduction in fair value, we continue to view the stock as undervalued with concerns surrounding glyphosate litigation creating too much pressure on the ...

Valens Research

Valens Equity Insights and Inflections - 2019 01 02

PSX currently trades below historical averages relative to UAFRS-based (Uniform) Assets, with a 1.0x Uniform P/B. However, even at these levels, the market is pricing in expectations for Uniform ROA to improve from current 3% levels in 2017 to 5% in 2022, accompanied by 2% Uniform Asset growth going forward. Meanwhile, analysts have more bullish expectations, projecting Uniform ROA to improve to 8% levels through 2019, accompanied by 11% Uniform Asset growth. However, management appears to have concerns about their profitability and projects that markets and analysts may not be factoring in, s...

Valens Research

BAYN:DEU - Embedded Expectations Analysis - 2019 01 02

Bayer AG (BAYN:DEU) currently trades below corporate averages relative to UAFRS-based (Uniform) Earnings, with a 13.8x Uniform P/E. At these levels, the market is pricing in bearish expectations for the firm, but management is confident about the sales growth and differentiation of Eylea and their Advantage animal health franchise Specifically, management is confident in the differentiated clinical profile of Eylea compared to competitor products, and in their substantial sales gains for Eylea. Additionally, they are confident that weaker Q3 results in their Advantage franchise are primarily...

Bayer AG - December 2017 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Bayer AG: Update to Discussion of Key Credit Factors

A detailed rationale for Bayer’s rating review for downgrade prompted by its offer to acquire Monsanto which would lead to significant increase in leverage.

Bayer AG - September 2017 (LTM): Peer Snapshot

Peer Snapshot:  Bayer AG - September 2017 (LTM) 1 December 2017 (in US millions) FYE Dec-15 FYE Dec-16 LTM Sep-17 FYE Dec-15 FYE Dec-16 LTM Sep-17 FYE Dec-15 FYE Dec-16 LTM Jun-17

Bayer AG - June 2017 (LTM): Peer Snapshot

Peer Snapshot: Bayer AG - June 2017 (LTM) 31 August 2017 (in US millions) FYE Dec-15 FYE Dec-16 LTM Jun-17 FYE Dec-15 FYE Dec-16 LTM Jun-17 FYE Dec-15 FYE Dec-16 LTM Mar-17

Bayer AG: Update to Discussion of Key Credit Factors

CORPORATES CREDIT OPINION 3 July 2017 Update RATINGS Bayer AG Domicile Germany Long Term Rating A3 , Possible Downgrade Type Senior Unsecured - Fgn Curr Outlook Rating(s) Under Review Please see the ratings section at the end of this report for more information. The ratings and outlook shown reflect information as of the publication date. Contacts Francois Lauras 44-20-7772-5397 VP-Sr Credit Offic

Jean-Jacques Le Fur

BAYER: Darolutamide not better than Xtandi in prostate cancer | NEUTRAL | EUR81

BAYER - NEUTRAL | EUR81(+24%) Darolutamide not better than Xtandi in prostate cancer Significant improvement of free survival Darolutamide will have to compete with Xtandi We are less optimistic than Bayer regarding peak sales Neutral rating reiterated

Damien Conover

Morningstar | BAYN Updated Forecasts and Estimates from 17 Jan 2019

During Bayer's capital markets day, the firm provided more details around one-time costs related to restructuring the business that led to a 3% reduction in our fair value estimate (with a slightly larger reduction to the ADR due to changes in currency rates). While we believe the restructuring makes strategic sense, the related one-time costs needed to implement the restructuring of over EUR 4 billion are higher than we expected. Despite the reduction in fair value, we continue to view the stock as undervalued with concerns surrounding glyphosate litigation creating too much pressure on the ...

Valens Research

Valens Equity Insights and Inflections - 2019 01 02

PSX currently trades below historical averages relative to UAFRS-based (Uniform) Assets, with a 1.0x Uniform P/B. However, even at these levels, the market is pricing in expectations for Uniform ROA to improve from current 3% levels in 2017 to 5% in 2022, accompanied by 2% Uniform Asset growth going forward. Meanwhile, analysts have more bullish expectations, projecting Uniform ROA to improve to 8% levels through 2019, accompanied by 11% Uniform Asset growth. However, management appears to have concerns about their profitability and projects that markets and analysts may not be factoring in, s...

Valens Research

BAYN:DEU - Embedded Expectations Analysis - 2019 01 02

Bayer AG (BAYN:DEU) currently trades below corporate averages relative to UAFRS-based (Uniform) Earnings, with a 13.8x Uniform P/E. At these levels, the market is pricing in bearish expectations for the firm, but management is confident about the sales growth and differentiation of Eylea and their Advantage animal health franchise Specifically, management is confident in the differentiated clinical profile of Eylea compared to competitor products, and in their substantial sales gains for Eylea. Additionally, they are confident that weaker Q3 results in their Advantage franchise are primarily...

Damien Conover

Morningstar | BAYN Updated Forecasts and Estimates from 05 Dec 2018

During Bayer's capital markets day, the firm provided more details around one-time costs related to restructuring the business that led to a 3% reduction in our fair value estimate (with a slightly larger reduction to the ADR due to changes in currency rates). While we believe the restructuring makes strategic sense, the related one-time costs needed to implement the restructuring of over EUR 4 billion are higher than we expected. Despite the reduction in fair value, we continue to view the stock as undervalued with concerns surrounding glyphosate litigation creating too much pressure on the ...

1 director bought

A director at Bayer Ag bought 15,000 shares at 66.248EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...

Nurhayati Wan

Bayer AG

Nurhayati Wan

Bayer AG

Nurhayati Wan

Bayer AG

Nurhayati Wan

Bayer AG

Nurhayati Wan

Bayer AG

Bayer – Proxinvest Corporate Governance Rating ® : C

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Expert Corporate Governance Service (ECGS)

Proxy Report - 25/05/2018

General: On 14 September 2016, Bayer signed a definitive merger agreement with Monsanto Company, which provides for Bayer’s acquisition of all outstanding shares in Monsanto against a cash payment of USD 128.00 per share, see section 3.1 for details. Under German law, the transaction is not subject to shareholder approval. The shareholders of Monsanto approved the merger with the requisite majority on 13 December 2016. However, the transaction remains subject to customary closing conditions, including relevant antitrust and other regulatory approvals. The European Commission, has approved the ...

Expert Corporate Governance Service (ECGS)

Proxy Report - 25/05/2018

General: On 14 September 2016, Bayer signed a definitive merger agreement with Monsanto Company, which provides for Bayer’s acquisition of all outstanding shares in Monsanto against a cash payment of USD 128.00 per share, see section 3.1 for details. Under German law, the transaction is not subject to shareholder approval. The shareholders of Monsanto approved the merger with the requisite majority on 13 December 2016. However, the transaction remains subject to customary closing conditions, including relevant antitrust and other regulatory approvals. The European Commission, has approved the ...

Jérôme VINERIER

Analyse court terme - BAYER : La tendance de fond est clairement orientée à la baisse.

La tendance de fond est clairement orientée à la baisse. Le mouvement se poursuit. Le prochain objectif est à 66,62 €, puis 59,12 €. Le franchissement de 85,70 € remettrait en cause la suite de la baisse.

Jérôme VINERIER

Short term view - BAYER : The background trend is clearly bearish.

The background trend is clearly bearish. The movement goes on. The next target is at €66.62, then €59.12. Passing €85.70 would question the continuation of the fall.

Jérôme VINERIER

Analyse court terme - BAYER : La tendance de fond est clairement orientée à la baisse.

La tendance de fond est clairement orientée à la baisse. Le mouvement se poursuit. Le prochain objectif est à 66,62 €, puis 59,12 €. Le franchissement de 85,70 € remettrait en cause la suite de la baisse.

Jérôme VINERIER

Short term view - BAYER : The background trend is clearly bearish.

The background trend is clearly bearish. The movement goes on. The next target is at €66.62, then €59.12. Passing €85.70 would question the continuation of the fall.

Jérôme VINERIER

Medium term view - BAYER : The movement goes on.

The background trend is clearly bearish. The movement goes on. The next target is at €66.20, then €49.50. Passing €102.90 would question the continuation of the fall.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch